Post-vaccination T cell immunity to omicron.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 15 05 2022
accepted: 30 06 2022
entrez: 22 8 2022
pubmed: 23 8 2022
medline: 24 8 2022
Statut: epublish

Résumé

In late 2021, the omicron variant of SARS Coronavirus 2 (SARS-CoV-2) emerged and replaced the previously dominant delta strain. Effectiveness of COVID-19 vaccines against omicron has been challenging to estimate in clinical studies or is not available for all vaccines or populations of interest. T cell function can be predictive of vaccine longevity and effectiveness against disease, likely in a more robust way than antibody neutralization. In this mini review, we summarize the evidence on T cell immunity against omicron including effects of boosters, homologous versus heterologous regimens, hybrid immunity, memory responses and vaccine product. Overall, T cell reactivity in post-vaccine specimens is largely preserved against omicron, indicating that vaccines utilizing the parental antigen continue to be protective against disease caused by the omicron variant.

Identifiants

pubmed: 35990661
doi: 10.3389/fimmu.2022.944713
pmc: PMC9386871
doi:

Substances chimiques

COVID-19 Vaccines 0
Viral Vaccines 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

944713

Informations de copyright

Copyright © 2022 Jacobsen, Cobos Jiménez, Sitaras, Bar-Zeev, Čičin-Šain, Higdon and Deloria-Knoll.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cell. 2022 Mar 17;185(6):1041-1051.e6
pubmed: 35202566
Nat Med. 2021 Jul;27(7):1147-1148
pubmed: 34239135
Cell Rep Med. 2022 Jan 24;3(2):100529
pubmed: 35233550
mBio. 2022 Apr 26;13(2):e0361721
pubmed: 35229637
JAMA Neurol. 2022 Apr 01;79(4):399-404
pubmed: 35212717
Nature. 2022 Feb;602(7896):307-313
pubmed: 34937050
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
N Engl J Med. 2021 Sep 2;385(10):951-953
pubmed: 34260834
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Eur J Immunol. 2021 Dec;51(12):2708-3145
pubmed: 34910301
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
JAMA Netw Open. 2022 Apr 1;5(4):e2210871
pubmed: 35452102
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Open Forum Infect Dis. 2022 Apr 18;9(6):ofac138
pubmed: 35611346
Nature. 2022 Mar;603(7903):919-925
pubmed: 35090164
Cell Mol Immunol. 2022 Mar;19(3):447-448
pubmed: 35043006
Immunology. 2012 Jan;135(1):19-26
pubmed: 22044118
iScience. 2021 Dec 17;24(12):103467
pubmed: 34805783
Lancet Infect Dis. 2022 May;22(5):603-610
pubmed: 35176230
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Proc Natl Acad Sci U S A. 2022 May 17;119(20):e2118312119
pubmed: 35561224
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
Nature. 2021 Jan;589(7843):500-501
pubmed: 33479534
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Cell. 2022 Jan 6;185(1):113-130.e15
pubmed: 34921774
Cell Rep Med. 2021 Jul 20;2(7):100355
pubmed: 34230917
N Engl J Med. 2022 Feb 3;386(5):494-496
pubmed: 34965358
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Cell Rep Med. 2021 Jul 20;2(7):100354
pubmed: 34250512
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
Nat Commun. 2021 Nov 26;12(1):6871
pubmed: 34836955
Sci Immunol. 2022 Mar 25;7(69):eabo2202
pubmed: 35113647
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
Viruses. 2022 Jan 02;14(1):
pubmed: 35062283
Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2200592119
pubmed: 35858386
Immunity. 2021 Sep 14;54(9):2133-2142.e3
pubmed: 34453880
Clin Infect Dis. 2022 Feb 11;:
pubmed: 35147176
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
J Virol. 2019 Mar 5;93(6):
pubmed: 30626684
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
Sci Transl Med. 2022 Apr 20;14(641):eabn6150
pubmed: 35258323
Sci Immunol. 2021 Oct 15;6(64):eabl4509
pubmed: 34623900
mBio. 2022 Aug 10;:e0142322
pubmed: 35946814
N Engl J Med. 2021 Dec 30;385(27):2582-2585
pubmed: 34879193
PLoS Med. 2022 May 17;19(5):e1003991
pubmed: 35580156
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Sci Immunol. 2021 May 25;6(59):
pubmed: 34035118
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311
Nature. 2022 Mar;603(7901):493-496
pubmed: 35102312
EClinicalMedicine. 2021 Dec;42:101190
pubmed: 34870134
Front Immunol. 2022 Jan 26;13:801431
pubmed: 35154116
Nature. 2021 Aug;596(7871):268-272
pubmed: 34107529
PLoS Pathog. 2021 Dec 2;17(12):e1010022
pubmed: 34855916
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Nat Med. 2022 Mar;28(3):486-489
pubmed: 35051989
Signal Transduct Target Ther. 2022 Apr 28;7(1):141
pubmed: 35484110
Semin Immunol. 2021 Jun;55:101505
pubmed: 34711489
Nat Med. 2022 Mar;28(3):472-476
pubmed: 35042228
Nat Rev Immunol. 2022 Apr;22(4):236-250
pubmed: 34312520
Nature. 2022 Feb;602(7895):148-155
pubmed: 34875673
Cell Host Microbe. 2021 Nov 10;29(11):1611-1619.e5
pubmed: 34688376

Auteurs

Henning Jacobsen (H)

Department of Viral Immunology, Helmholtz Center for Infection Research, Braunschweig, Germany.

Viviana Cobos Jiménez (V)

Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States.

Ioannis Sitaras (I)

W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

Naor Bar-Zeev (N)

International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

Luka Čičin-Šain (L)

Department of Viral Immunology, Helmholtz Center for Infection Research, Braunschweig, Germany.
Centre for Individualised Infection Medicine (CIIM), a joint venture of HZI and MHH, Hannover, Germany.
German Centre for Infection Research (DZIF), Hannover-Braunschweig site, Germany.

Melissa M Higdon (MM)

International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

Maria Deloria-Knoll (M)

International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH